JP2022506686A5 - - Google Patents

Info

Publication number
JP2022506686A5
JP2022506686A5 JP2021524226A JP2021524226A JP2022506686A5 JP 2022506686 A5 JP2022506686 A5 JP 2022506686A5 JP 2021524226 A JP2021524226 A JP 2021524226A JP 2021524226 A JP2021524226 A JP 2021524226A JP 2022506686 A5 JP2022506686 A5 JP 2022506686A5
Authority
JP
Japan
Application number
JP2021524226A
Other languages
Japanese (ja)
Other versions
JP2022506686A (ja
JPWO2020097258A5 (https=
JP7671245B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060148 external-priority patent/WO2020097258A1/en
Publication of JP2022506686A publication Critical patent/JP2022506686A/ja
Publication of JPWO2020097258A5 publication Critical patent/JPWO2020097258A5/ja
Publication of JP2022506686A5 publication Critical patent/JP2022506686A5/ja
Priority to JP2024226318A priority Critical patent/JP2025041790A/ja
Application granted granted Critical
Publication of JP7671245B2 publication Critical patent/JP7671245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524226A 2018-11-06 2019-11-06 ピリダジノン化合物およびその使用 Active JP7671245B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024226318A JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756552P 2018-11-06 2018-11-06
US62/756,552 2018-11-06
PCT/US2019/060148 WO2020097258A1 (en) 2018-11-06 2019-11-06 Pyridazinone compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024226318A Division JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Publications (4)

Publication Number Publication Date
JP2022506686A JP2022506686A (ja) 2022-01-17
JPWO2020097258A5 JPWO2020097258A5 (https=) 2022-11-14
JP2022506686A5 true JP2022506686A5 (https=) 2022-11-14
JP7671245B2 JP7671245B2 (ja) 2025-05-01

Family

ID=69326619

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524226A Active JP7671245B2 (ja) 2018-11-06 2019-11-06 ピリダジノン化合物およびその使用
JP2024226318A Pending JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024226318A Pending JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Country Status (7)

Country Link
US (2) US11390606B2 (https=)
EP (1) EP3877367B1 (https=)
JP (2) JP7671245B2 (https=)
CN (1) CN113272280B (https=)
AU (1) AU2019374812B2 (https=)
CA (1) CA3118904A1 (https=)
WO (1) WO2020097258A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164852A1 (en) * 2018-02-20 2019-08-29 Edgewise Therapeutics, Inc. Methods and compositions for treating movement disorders
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP3914245A4 (en) 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC-1 MODULATORS AND USES THEREOF
EP4149621B1 (en) * 2020-05-13 2024-10-30 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
WO2021231565A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
EP4149465A1 (en) * 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149466A1 (en) * 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149467A1 (en) * 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
CN120302976A (zh) 2022-09-09 2025-07-11 艾知怀斯治疗学公司 用于治疗神经肌肉病状的哒嗪酮组合物
KR20250121977A (ko) * 2023-01-04 2025-08-12 시젱 하이스코 파마수티칼 씨오., 엘티디. 피리다지논 헤테로사이클릭 화합물 Myosin II 억제제 및 이의 용도
WO2025167826A1 (zh) * 2024-02-06 2025-08-14 西藏海思科制药有限公司 三环化合物作为Myosin II抑制剂及其用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6140270A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
DD286354A5 (de) 1989-08-08 1991-01-24 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
CN1326852C (zh) * 2003-03-07 2007-07-18 兴和株式会社 苯并呋喃衍生物
JP4890439B2 (ja) 2005-03-07 2012-03-07 杏林製薬株式会社 ピラゾロピリジン−4−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012021707A2 (en) * 2010-08-11 2012-02-16 The Regents Of The University Of California Premature-termination-codons readthrough compounds
BR112013007499A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
CN103570730A (zh) 2012-08-01 2014-02-12 中国科学院上海药物研究所 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US9216180B2 (en) 2012-10-02 2015-12-22 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
EP2953944B1 (en) * 2013-02-07 2017-04-26 Merck Patent GmbH Pyridazinone-amides derivatives
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014189634A1 (en) 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensins in muscular dystrophy
US10555960B2 (en) 2015-06-05 2020-02-11 Ptc Therapeutics, Inc. Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
JP7007199B2 (ja) 2015-06-10 2022-02-10 アソシアシオン・アンスティテュ・ドゥ・ミオロジー デュシェンヌ型筋ジストロフィーのための併用療法
CN106467495A (zh) * 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
WO2017046117A1 (en) * 2015-09-15 2017-03-23 Abbvie Inc. Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
AU2017348186A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating CFTR
EP3600322A1 (en) 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
TWI902102B (zh) 2017-04-06 2025-10-21 美商富曼西公司 殺真菌之噁二唑
US20180303821A1 (en) 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules
BE1025518B1 (fr) 2017-08-30 2019-04-03 E2 Drives Sa Groupe motopropulseur
EP3700516B1 (en) 2017-10-27 2024-01-24 Sonic Master Limited Inhibitors of dux4 induction for regulation of muscle function
CN112166181B (zh) 2018-05-17 2024-03-08 保尔特纺织品公司 用于改善重组蛋白分泌的sec经修饰菌株
EP4685140A1 (en) 2018-06-04 2026-01-28 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
EP3828174A4 (en) 2018-07-19 2022-08-17 Sumitomo Pharma Co., Ltd. PYRIDAZINONE DERIVATIVE
CN108947912B (zh) 2018-07-31 2021-10-01 中国人民解放军总医院 一种靶向Neddylation通路的抗肿瘤化合物
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
EP4149621B1 (en) 2020-05-13 2024-10-30 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
WO2021231565A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
EP4149465A1 (en) 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149467A1 (en) 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149466A1 (en) 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
JP7694135B2 (ja) 2021-05-11 2025-06-18 株式会社大林組 接続構造及び接続方法
EP4433473A1 (en) 2021-11-17 2024-09-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
CN119317621A (zh) 2022-05-11 2025-01-14 艾知怀斯治疗学公司 制备哒嗪酮化合物的方法
CN120302976A (zh) 2022-09-09 2025-07-11 艾知怀斯治疗学公司 用于治疗神经肌肉病状的哒嗪酮组合物
JP2025040270A (ja) * 2023-09-11 2025-03-24 共同印刷株式会社 赤外線遮断性生地

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
JP2022506686A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112021017732A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)